These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38682605)

  • 1. Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross-Sectional Study.
    Janak JC; Ross RD; Brady BL; Palmer L; Howard JT; Baker JF
    Arthritis Care Res (Hoboken); 2024 Sep; 76(9):1287-1293. PubMed ID: 38682605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Hernández-Cruz B; Otero-Varela L; Freire-González M; Busquets-Pérez N; García González AJ; Moreno-Ramos M; Blanco-Madrigal JM; Manrique-Arija S; Perez-Pampin E; Ruiz-Montesino D; Sánchez-Alonso F; Sanchez-Piedra C; Castrejón I;
    Ann Rheum Dis; 2024 Aug; 83(9):1189-1199. PubMed ID: 38594056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs.
    Singh N; Gold LS; Lee J; Wysham KD; Andrews JS; Makris UE; England BR; George MD; Baker JF; Jarvik J; Heagerty PJ; Singh S
    Arthritis Care Res (Hoboken); 2024 May; 76(5):627-635. PubMed ID: 38116680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
    Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
    Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
    Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
    Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
    Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
    Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
    Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
    Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
    Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Front Immunol; 2024; 15():1395968. PubMed ID: 38846940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis.
    Chen YW; Chen HH; Huang WN; Chen JP; Chen YH; Chen YM
    Clin Rheumatol; 2024 Jan; 43(1):117-128. PubMed ID: 37658935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
    Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
    Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Lauper K; Iudici M; Mongin D; Bergstra SA; Choquette D; Codreanu C; Cordtz R; De Cock D; Dreyer L; Elkayam O; Hauge EM; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Kristianslund EK; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Strangfeld A; Verschueren P; Courvoisier DS; Finckh A
    Ann Rheum Dis; 2022 Oct; 81(10):1358-1366. PubMed ID: 35705376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study.
    Strunz PP; Risser LM; Englbrecht M; Witte T; Froehlich M; Schmalzing M; Gernert M; Hueper S; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Welcker M; Kleinert S
    Front Immunol; 2024; 15():1445680. PubMed ID: 39238648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: A multi-centre cohort study.
    Tong X; Shen CY; Jeon HL; Li Y; Shin JY; Chan SC; Yiu KH; Pratt NL; Ward M; Lau CS; Wong IC; Li X; Lai EC
    J Intern Med; 2023 Sep; 294(3):314-325. PubMed ID: 37282790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population.
    Popa CD; Opdam MAA; den Broeder N; van Ballegooijen H; Mulder K; van de Wiel KM; van Herwaarden N; Wientjes MHM; den Broeder AA
    Rheumatology (Oxford); 2024 Aug; 63(8):2142-2146. PubMed ID: 37796830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.